

Supplementary Material

Spastic Paraplegia 20 and Serine/Threonine Protein Kinase 31 Expression for the Detection of Colorectal Cancer

Nivin A. Hassan^a Naglaa K. Idriss^b Noha Gaber^c Abeer Ibrahim^d
Mariana A. Tawfeek^a Eman Mossad^c Aliaa A. Mosa^b Eman H. Ahmed^c
Sally A. Sayed^e Heba A. Ahmed^f Amal A. M. Mohamed^b

^aPharmacology and Experimental Oncology Unit, Cancer Biology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt, ^bDepartment of Medical Biochemistry, Faculty of Medicine, Assiut University, Assiut, Egypt, ^cOncological Clinical Pathology Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt, ^dMedical Oncology and Hematological Malignancy Department, South Egypt Cancer Institute, Assiut University, Assiut, Egypt, ^eMedical Physiology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, ^fClinical Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt

Supplementary Table S1: Fold Change of the SPG-20 and STK-31 Marker among the studied Cohort.

No significant differences in fold change of SPG20 between cases and control. Significant differences in fold change of STK31 cases double the control

Fold Change			
	Control	CRC Cases	P-value*
	(n = 50)	(n = 50)	
RQ-SPG-20			
• Mean ± SE	2.51 ± 1.1	1.51 ± 0.3	= 0.673
• Median (IQR)	1 (0.8)	0.7 (1.7)	
RQ-STK-31			
• Mean ± SE	1.99 ± 0.5	2.93 ± 0.5	= 0.038
• Median (IQR)	1 (0.8)	1.9 (2)	

*Mann-Whitney U test was used to compare the mean difference between the two groups